SNJ Pharma Inc. (SNJ) was founded to revolutionize the treatment of thrombotic disorders with SNJ101, the first plasmin-independent thrombolytic agent.
We are determined to overcome the limitations of current FDA- approved tPA and TNK therapies by eliminating their associated bleeding complications and providing a new treatment option for patients suffering thrombotic episodes.
SNJ was founded in 2020 by Dr. Hyeon Kim, the inventor of patent for SNJ101, at the BioLabs-LA within the Lundquist Institute for Biomedical Innovation at Harbor UCLA.
The company’s portfolio, which includes SNJ101 for thrombolysis, aims to address unmet medical needs related to severe thrombotic and thromboembolic conditions, with a focus on improved safety and decreased side effects.
Copyright © 2023 SNJ Pharma Inc. - All Rights Reserved.